Metal-on-metal Hip Prostheses: Do They Have Systemic Effects?
NCT ID: NCT02382835
Last Updated: 2016-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
800000 participants
OBSERVATIONAL
2015-03-31
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We plan to link the National Joint Registry for England, Wales and Northern Ireland to the National Heart Failure Audit and GP records.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metal on Metal Versus Ceramic on Metal Hip Replacement
NCT00208494
Metal Ions in Ceramic on Metal Total Hip Arthroplasty
NCT01437124
Neurotoxicity and Cardiotoxicity in Total Joint Arthroplasty
NCT04166539
Outcome of Total Hip Replacement in Patients With Chronic Renal Disease
NCT03522285
Effect of Cemented Stem Design on Periprosthetic Bone Mass Following Primary Total Hip Arthroplasty
NCT00293605
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Aims: We aim to establish the prevalence of cardiac, endocrine, neurological disorders, and distant site fracture history (forearm, spine) in recipients of MOMHR, and establish whether this differs to that found in the general population of the same age and sex distribution, and also to recipients of hip replacement using a conventional bearing.
Methods: We will use NJR data linked to the Clinical Practice Research Dataset (CPRD) to establish the prevalence of cardiac, endocrine, neurological disorders, and distant site fracture history (forearm, spine) in the 3 study populations.
Outcome measures: All defined as the event occurring at any point following MOMHR surgery.
Primary outcome measure:
History of cardiac failure, as defined by IDC9-CM code 150, or equivalent CPRD codes
Secondary outcome measures:
1. History of treated or untreated acquired hypothyroidism (ICD9 244.8), or equivalent
2. Fracture history at a site distant to the ipsilateral hip (ICD9 820.00 to 826.1)
3. Acquired neurological disorders, including extra-pyramidal disorders (ICD9 332 and 333), spinocerebellar degenerative disease (ICD9 334) and other paralytic syndromes (ICD9 344)
4. Acquired blindness and low vision (ICD9 369)
5. Acquired hearing loss (ICD9 389)
Analyses will be conducted with age, sex, and joint disease diagnosis matching. Analyses will be stratified by sex to establish whether any differences are sex specific, and adjusted for age and other comorbidities, including history of type 2 diabetes, pre-existing ischaemic heart disease, hypertension, and pre-existing use of drugs that may affect cardiac function.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metal-on-Metal Hip Replacement
No interventions assigned to this group
Other Hip Replacement
Other types of hip replacement, such as metal-on-polyethylene or ceramic-on-ceramic
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have at least 6 (or 12) months of valid follow up in the primary care database.
* Primary or revision hip replacement on National Joint Registry (NJR) database occurring to during the period of availability of metal-on-metal implants, and during the available primary care follow up period for that patient.
* NHS number and other linkage identifiers available for both data sources
* Patient consent to NJR use of patient data (which is present for 99.6% of records on NJR)
Exclusion Criteria
* Patients whose hips were implanted in the past 6 months - this exclusion criterion will be implemented post linkage of the data.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University College, London
OTHER
Royal National Orthopaedic Hospital NHS Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Professor Alister Hart
Professor of Orthopaedics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal National Orthopaedic Hospital
Stanmore, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.